ArticleFrontiers in medicine2025
Identification of key genes in osteoarthritis development: biomarker discovery and therapeutic targets.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Construction of biomimetic gradient-structured cartilage organoids and mechanistic study of their application for cartilage rejuvenation.Bioactive materials · 2026Article
- Single Intra-Articular Anakinra (IL-1Ra) Versus Betamethasone in Rabbit Post-Traumatic Knee Osteoarthritis: IL-8 Suppression and Chondrocyte Viability.Cell biochemistry and function · 2026Article
- Alpha2EQ downregulates proinflammatory cytokine and chemokine gene expression in cultured synovial fibroblasts.American journal of veterinary research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoarthritis (OA) is the most common joint disorder and a leading cause of disability in the older adult. Early diagnosis and treatment are crucial for effective disease management and improved outcomes. This study aims to identify key genes involved in OA progression using bioinformatics, which may serve as diagnostic biomarkers and therapeutic targets. Methods: Synovial tissue sequencing data (GSE1919, GSE55235, GSE82107) were retrieved from the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were analyzed using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) network analysis. ROC curve analysis was used to assess diagnostic potential, and results were validated using the GSE29746 dataset and synovial tissues from five OA patients and controls. Results: A total of 33 common DEGs were identified across three datasets. Four hub genes (CXCL8, CXCL2, DUSP5, TNFSF11) showed high diagnostic potential [area under the receiver operating characteristic curve (AUC) > 0.8]. These genes were also linked to potential therapeutic agents, including lipopolysaccharide and acetaminophen. Conclusion: CXCL8, CXCL2, DUSP5, and TNFSF11 represent novel multi-functional biomarkers that advance OA research by addressing two critical limitations of prior biomarker studies: (1) overcoming the diagnostic inadequacy of single-biomarker approaches through synergistic clusters, and (2) revealing an unreported integrative mechanism linking inflammatory pathways (CXCL8/2) and bone remodeling processes (TNFSF11/DUSP5). This dual diagnostic-therapeutic potential significantly expands the clinical applicability of OA biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.